Neurocrine Biosciences, Inc. (NBIX)’s Stock Formed A Several Months Double Top Chart Pattern

December 7, 2017 - By Stephen Andrade

Investors sentiment increased to 1.25 in Q2 2017. Its up 0.22, from 1.03 in 2017Q1. It is positive, as 33 investors sold Neurocrine Biosciences, Inc. shares while 59 reduced holdings. 44 funds opened positions while 71 raised stakes. 91.92 million shares or 11.33% more from 82.57 million shares in 2017Q1 were reported.
Ardsley Advisory Ptnrs owns 5,000 shares. Goldman Sachs Group has 0.03% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Morgan Stanley owns 52,897 shares for 0% of their portfolio. The Pennsylvania-based Vanguard Gp Inc has invested 0.02% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Moreover, Utah Retirement System has 0.02% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 16,000 shares. 7.17 million were reported by Price T Rowe Assocs Md. Bank & Trust Of Ny Mellon Corporation has invested 0.03% in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Weiss Multi has 0.06% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 31,000 shares. Panagora Asset Mgmt Incorporated holds 0% or 900 shares. Barclays Public Ltd Liability Company holds 20,191 shares. Amalgamated Natl Bank holds 0.02% or 16,151 shares. Moreover, Capstone Asset has 0.01% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 4,666 shares. Moreover, Franklin Incorporated has 0.08% invested in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 3.38M shares. Rhenman Ptnrs Asset Ab, a Sweden-based fund reported 120,000 shares. Fmr Ltd Liability Com reported 13.21 million shares or 0.08% of all its holdings.

The chart of Neurocrine Biosciences, Inc. (NBIX) shows a double top with $77.58 target or 7.00 % above today’s $72.50 share price. The 9 months chart pattern indicates low risk for the $6.42B company. It was reported on Dec, 7 by If the $77.58 price target is reached, the company will be worth $449.12M more. Double tops are rare but powerful chart patterns.

The stock increased 3.85% or $2.69 during the last trading session, reaching $72.5. About 519,820 shares traded. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has risen 12.51% since December 7, 2016 and is uptrending. It has underperformed by 4.19% the S&P500.

Analysts await Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to report earnings on February, 13. They expect $-0.03 EPS, up 94.12 % or $0.48 from last year’s $-0.51 per share. After $-0.13 actual EPS reported by Neurocrine Biosciences, Inc. for the previous quarter, Wall Street now forecasts -76.92 % EPS growth.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Ratings Coverage

Among 12 analysts covering Neurocrine Biosci (NASDAQ:NBIX), 12 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neurocrine Biosci had 38 analyst reports since August 18, 2015 according to SRatingsIntel. Leerink Swann maintained Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on Tuesday, October 10 with “Buy” rating. The firm earned “Buy” rating on Tuesday, October 18 by Needham. On Friday, August 4 the stock rating was maintained by Oppenheimer with “Buy”. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has “Perform” rating given on Tuesday, November 22 by Oppenheimer. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) earned “Buy” rating by Oppenheimer on Tuesday, November 14. Needham maintained the stock with “Buy” rating in Friday, September 15 report. BMO Capital Markets maintained the shares of NBIX in report on Thursday, August 3 with “Buy” rating. The rating was maintained by Piper Jaffray on Wednesday, October 25 with “Buy”. Piper Jaffray maintained it with “Buy” rating and $68.0 target in Thursday, August 24 report. The rating was maintained by BMO Capital Markets with “Buy” on Wednesday, November 1.

More notable recent Neurocrine Biosciences, Inc. (NASDAQ:NBIX) news were published by: which released: “Neurocrine Biosciences to Present at the 29th Annual Piper Jaffray Healthcare …” on November 21, 2017, also with their article: “Neurocrine Biosciences to Present at the BMO Capital Markets 2017 …” published on December 07, 2017, published: “Neurocrine Biosciences to Present at the Jefferies 2017 London Healthcare …” on November 08, 2017. More interesting news about Neurocrine Biosciences, Inc. (NASDAQ:NBIX) were released by: and their article: “Neurocrine Biosciences Presents Long-term Data Analyses from Open-label KINECT …” published on December 04, 2017 as well as‘s news article titled: “Neurocrine Biosciences Appoints Matt Abernethy as Chief Financial Officer” with publication date: November 20, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.